ClinicalTrials.Veeva

Menu

REMINISCENCES and EMOTIONS : Reminiscence Triggered by Virtual Reality for Older Adults With Mood Disorders

C

Centre Hospitalier Universitaire de Nice

Status

Completed

Conditions

Alzheimer Disease
Mood Disorders
Virtual Reality

Treatments

Procedure: virtual reality session

Study type

Interventional

Funder types

Other

Identifiers

NCT04442594
20-PP-11

Details and patient eligibility

About

Presentation & Pre-screening of the control group / reminiscence group Patient/resident pre-screening team meeting for the study Explanation and proposal of the study to patients and their families Signature of resident/patient and family consents Audit of inclusion and non-inclusion criteria Inclusion Medical advice for VR Clinical interview with the family or legal guardian for an accurate life history + an anamnesis interview (psychologist or doctor) with the patient or resident.

Creation of video contents Creation of personalized video contents Clinical scales review Evaluation of the number of psychotropic molecules prescribed (coordinating doctor, general practitioner, geriatrician)

  • Pre-test phase with the patient for the use of the VR headset
  • Randomisation
  • Session procedure As previously mentioned, the virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.

Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).

The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.

The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.) with a different virtual environment every 3 weeks.

During the session, note will be taken on the subject's speech. The session will also be filmed and/or recorded with a prior signed agreement by the patient or his representative.

  • Last session (S6) Review of clinical scales (re-testing) Re-evaluation of drug prescriptions

Enrollment

27 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female aged 65 or older
  • Accompanied in day care or in the geriatric structure of the CHU of Nice (EHPAD-USLD)
  • Mild to moderate cognitive impairment
  • Diagnostic criteria for Alzheimer's disease, NINCDS-ADRDA probably,
  • Positive score on at least one of the following rating scales :
  • NPI-ES depression/dysphoria and anxiety items + GDS 15 Patients
  • IA caregiver = 2 on one of 2 dimensions + IA patient = 2 on one of 2 dimensions

Exclusion criteria

  • Diagnosed psychiatric pathology
  • Disabling sensory disorders such as DMLA
  • Significant hearing loss
  • Subjects with risk of photosensitive epilepsy or dizziness. Subjects with Lewy body dementia

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

27 participants in 2 patient groups

personalized video
Experimental group
Description:
Each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families).
Treatment:
Procedure: virtual reality session
generic vidéo
Active Comparator group
Description:
The subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.)
Treatment:
Procedure: virtual reality session

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems